| PIRS Stock | | | USD 16.83 0.24 1.41% |
Pieris Pharmaceuticals financial indicator trend analysis is much more than just breaking down Pieris Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Pieris Pharmaceuticals is a good investment. Please check the relationship between Pieris Pharmaceuticals Accounts Payable and its Non Currrent Assets Other accounts. Check out
Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pieris Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in metropolitan statistical area.
For more information on how to buy Pieris Stock please use our
How to Invest in Pieris Pharmaceuticals guide.
Accounts Payable vs Non Currrent Assets Other
Accounts Payable vs Non Currrent Assets Other Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of
Pieris Pharmaceuticals Accounts Payable account and
Non Currrent Assets Other. At this time, the significance of the direction appears to have strong relationship.
The correlation between Pieris Pharmaceuticals' Accounts Payable and Non Currrent Assets Other is 0.69. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Non Currrent Assets Other in the same time period over historical financial statements of Pieris Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Pieris Pharmaceuticals' Accounts Payable and Non Currrent Assets Other is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of Pieris Pharmaceuticals are associated (or correlated) with its Non Currrent Assets Other. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Currrent Assets Other has no effect on the direction of Accounts Payable i.e., Pieris Pharmaceuticals' Accounts Payable and Non Currrent Assets Other go up and down completely randomly.
Correlation Coefficient | 0.69 |
| Relationship Direction | Positive |
| Relationship Strength | Significant |
Accounts Payable
An accounting item on the balance sheet that represents Pieris Pharmaceuticals obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Pieris Pharmaceuticals are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.
Non Currrent Assets Other
Assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents.
Most indicators from Pieris Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Pieris Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out
Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pieris Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in metropolitan statistical area.
For more information on how to buy Pieris Stock please use our
How to Invest in Pieris Pharmaceuticals guide.
Issuance Of Capital Stock is likely to gain to about 22.9
M in 2024, whereas
Selling General Administrative is likely to drop slightly above 13.5
M in 2024.
Pieris Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Pieris Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Pieris Pharmaceuticals fundamental ratios Accounts
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Additional Tools for Pieris Stock Analysis
When running Pieris Pharmaceuticals' price analysis, check to
measure Pieris Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pieris Pharmaceuticals is operating at the current time. Most of Pieris Pharmaceuticals' value examination focuses on studying past and present price action to
predict the probability of Pieris Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pieris Pharmaceuticals' price. Additionally, you may evaluate how the addition of Pieris Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.